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bjectives This serial angiographic study evaluated the incidence and predictors of late restenosis
fter sirolimus-eluting stent (SES) implantation.
ackground Previous studies showed late restenosis (i.e., late catch-up phenomenon) after implan-
ation of 7-hexanoyltaxol-eluting stents and nonpolymeric, paclitaxel-eluting stents.
ethods Between August 2004 and December 2006, SES implantation was performed in 1,393
atients with 2,008 lesions, in whom 8-month and 2-year follow-up coronary angiography were
lanned.
esults Of 2,008 lesions, 1,659 (83%) underwent 8-month follow-up angiography (8.3  2.2
onths). Restenosis was observed in 122 lesions (7.4%). Coronary angiography 2 years (1.9  0.4
ears) after SES deployment was performed in 1,168 lesions (74% of lesions without restenosis at
-month follow-up angiography). Late restenosis was observed in 83 lesions (7.1%). There was sig-
iﬁcant decrease in minimum luminal diameter (MLD) between 8-month and 2-year follow-up
2.56  0.56 mm vs. 2.35  0.71 mm, p  0.001). Multivariate analysis showed in-stent restenosis
efore SES implantation and MLD at 8-month follow-up as independent predictors of late restenosis.
onclusions Between 8-month and 2-year follow-up after SES implantation, MLD decreases, which
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124rug-eluting stents have significantly reduced in-stent re-
tenosis (1–3). However, there is a concern about the
urability of efficacy (4–9). Previous studies showed late
estenosis (i.e., late catch-up phenomenon) after implanta-
ion of 7-hexanoyltaxol-eluting stents (4) and nonpoly-
eric, paclitaxel-eluting stents (5). Long-term porcine data
emonstrated late catch-up phenomenon after sirolimus-
luting stent (SES) implantation (7). Recently, Byrne et al.
8,9) have shown late restenosis after SES implantation.
urther information regarding this concern is required. This
erial angiographic study evaluated the incidence and pre-
ictors of late restenosis after SES implantation.
ethods
tudy patients. From August 2004, we started a single-
enter registry to evaluate the incidence of late restenosis
fter SES implantation. We planned 8-month and 2-year
ollow-up coronary angiography in all patients undergoing
ES implantation at Miyazaki Medical Association Hospi-
al in Japan, if there were no contraindications for follow-up
angiography. This study was ap-
proved by the local council on
human research.
Between August 2004 and
December 2006, 1,393 patients
with 2,008 lesions underwent
SES implantation. Percutaneous
coronary intervention was per-
formed after written informed
consent was obtained. Implanta-
tion of SES was performed ac-
cording to current guidelines
10). All patients received aspirin 100 mg daily before the
rocedure and continued indefinitely. Patients were treated
oncomitantly with ticlopidine 100 mg twice daily (standard
ose in Japan) (11) or clopidogrel 75 mg daily for at least 3
onths.
ngiographic and clinical follow-up. According to the study
rotocol, follow-up angiography was planned at 8 months
nd 2 years after the procedure. Follow-up angiography
erformed at 6 to 12 months was considered 8-month
ollow-up angiography. When follow-up angiography per-
ormed at 5 months or earlier showed restenosis, it was
ncluded into 8-month follow-up angiography. If it showed
o restenosis, patients were encouraged to undergo
-month follow-up angiography. Follow-up angiography
erformed at 19 months or later was considered 2-year
ollow-up angiography. Coronary angiography performed
3 to 18 months after stenting was included into 2-year
ollow-up angiography if it demonstrated restenosis in
esions with no restenosis at 8-month follow-up. The
bbreviations
nd Acronyms
I  myocardial infarction
LD  minimum lumen
iameter
ES  sirolimus-eluting
tent(s)
LR  target lesion
evascularizationecond follow-up angiography in lesions with restenosis at v-month follow-up was not considered 2-year follow-up
ngiography.
Clinical and laboratory demographic information was
btained from hospital charts that were reviewed by inde-
endent research personnel who were unaware of the
bjectives of the study. Meticulous follow-up was per-
ormed to obtain follow-up information. Their family
nd/or referring physicians were contacted, if we could not
eep in touch with them. Clinical follow-up 8 months and
years from the index procedure was obtained in all
atients. The occurrence of major adverse cardiac events was
ecorded including all-cause and cardiac death, myocardial
nfarction (MI), and target lesion revascularization (TLR);
hese were adjudicated by accompanying source documen-
ation. Stent thrombosis was defined as: 1) the presence of
n acute coronary syndrome with angiographic or autopsy
vidence of thrombus or occlusion, 2) unexplained deaths
ithin 30 days after the procedure, or 3) acute MI involving
he target-vessel territory without angiographic confirma-
ion (12). Stent thrombosis was also classified as early (0 to
0 days), late (31 to 360 days), and very late (360 days).
ngiographic analysis. An independent analysis using a
omputer-assisted, automated, edge-detection algorithm
CAAS II system, Pie Medical, Maastricht, the Nether-
and) was performed by an experienced technician who was
upervised by an interventionalist. Standard qualitative and
uantitative definitions and measurements were used. The
uter diameter of the contrast-filled catheter was used as the
alibration and the minimum lumen diameter (MLD) was
btained from the single worst view. Angiographic resteno-
is was defined as diameter stenosis 50% within a previ-
usly stented segment (stent and 5 mm proximal and distal)
t follow-up angiography. All cases with angiographic
vidence of stent thrombosis were not considered restenosis.
ate angiographic restenosis was defined as diameter ste-
osis 50% at 2-year follow-up angiography in lesions of
50% diameter stenosis at 8-month follow-up angiogra-
hy. Late luminal loss was defined as the difference in MLD
etween post-procedure and 8-month follow-up. Delayed
ate luminal loss was the difference in MLD between
-month and 2-year follow-up.
tatistical analysis. Statistical analysis was performed with
tatView 5.0 software (SAS Institute, Cary, North Caro-
ina). Continuous variables were expressed as mean  SD
nd categorical variables as frequency (%). Categorical
ariables were compared with chi-square statistics. Contin-
ous variables were compared using Student t tests except
or serial changes in MLD between lesions with and
ithout late restenosis. It was compared with 2-way re-
eated measures analysis of variance. If it showed a signif-
cant effect or interaction, 1-way repeated-measures analysis
f variance with post-hoc Fisher protected least squares
ifference test was performed to study specifically the
ariations over time of MLD, and a factorial analysis of
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125ariance was performed to study the effect of late restenosis
n individual variables (13). A 2-sided p  0.05 was
onsidered statistically significant. Multivariate logistic re-
ression was used to identify independent predictors of late
estenosis. Variables in Tables 1, 2, and 3 with p value0.1
etween lesions with and without late restenosis were
ncluded in the multivariate model.
esults
aseline clinical characteristics in 1,393 patients undergoing
ES implantation are shown in Table 4. Patients who
nderwent 2-year follow-up angiography were younger than
hose who did not. In lesions undergoing 2-year follow-up
ngiography, the lower incidence of prior MI and prior
oronary artery bypass surgery was observed in lesions with
ate restenosis than in those without late restenosis (Table
). Angiographic and procedural characteristics are shown
n Table 5. The lower incidence of moderate or severe
alcification and the higher incidence of in-stent restenosis
ere observed in lesions with than without 2-year follow-up
ngiography. Direct stenting and post-dilation were per-
ormed more frequently in lesions with than without 2-year
ollow-up angiography. In lesions undergoing 2-year
ollow-up angiography, there were smaller stent diameter,
aximum balloon diameter, and reference vessel diameter
efore the procedure in lesions with late restenosis than in
hose without late restenosis (Table 2).
Table 1. Baseline Characteristics
2-Year Follow-Up
p ValueRestenosis No Restenosis
Age, yrs 66.5 10.7 66.1 8.9 0.66
Male 62 (74.7) 821 (75.7) 0.84
Hypertension 70 (84.3) 862 (79.4) 0.28
Hypercholesterolemia 38 (45.8) 575 (53.0) 0.20
Diabetes mellitus 35 (42.2) 410 (37.8) 0.43
Oral hypoglycemic 28 (33.7) 359 (33.1) 0.90
Insulin treatment 7 (8.4) 51 (4.7) 0.13
Current smokers 20 (24.1) 302 (27.8) 0.46
Chronic renal failure* 0 (0) 33 (3.0) 0.16
Dialysis-dependent 0 (0) 12 (1.1) 0.99
Prior myocardial infarction 19 (22.9) 402 (37.1) 0.01
Prior PCI 48 (57.8) 684 (63.0) 0.34
Prior bypass surgery 1 (1.2) 73 (6.7) 0.05
Multivessel disease 38 (45.8) 568 (52.4) 0.25
Clinical presentation at initial procedure 0.56
Acute myocardial infarction 10 (12.0) 135 (12.4)
Unstable angina 10 (12.0) 93 (8.6)
Stable angina 63 (75.9) 857 (79.0)
Values are n (%) or mean SD. *Creatinine1.5 mg/l.fPCI percutaneous coronary intervention.Until 8-month follow-up, all-cause and cardiac deaths
ere observed in 20 (1.4%) and 12 patients (0.9%), respec-
ively. There were 35 all-cause (2.5%) and 8 cardiac deaths
0.6%) between 8-month and 2-year follow-up. Myocardial
nfarction was observed in 7 patients (0.5%) until 8-month
ollow-up and in 7 patients (0.5%) between 8-month and
-year follow-up. Target lesion revascularization was per-
ormed in 94 lesions (4.7%) undergoing 8-month follow-up
ngiography and in 62 lesions (3.1%) undergoing 2-year
ollow-up angiography. Early stent thrombosis was ob-
erved in 3 patients (0.22%). There was no late stent
hrombosis. Very late stent thrombosis was observed in 7
atients (0.50%).
Of 2,008 lesions, 1,659 (83%) underwent 8-month
Table 2. Angiographic and Procedural Characteristics
2-Year Follow-Up
p ValueRestenosis No Restenosis
Vessels treated 0.91
Left anterior descending 36 (43.4) 517 (47.7)
Left circumﬂex 17 (20.5) 227 (20.9)
Right coronary artery 28 (33.7) 321 (29.6)
Left main artery 2 (2.4) 19 (1.8)
Saphenous vein graft 0 (0) 1 (0.1)
Ostial location 7 (8.4) 110 (10.1) 0.62
Bifurcation 19 (22.9) 246 (22.7) 0.96
Thrombotic lesion 9 (10.8) 81 (7.5) 0.27
Moderate or severe calciﬁcation 13 (15.7) 178 (16.4) 0.86
Chronic total occlusion 2 (2.4) 25 (2.3) 0.99
In-stent restenosis 12 (14.5) 91 (8.4) 0.06
AHA/ACC type B2 or C 67 (80.7) 917 (84.2) 0.40
Intravascular ultrasound 68 (81.9) 900 (82.9) 0.81
Rotational atherectomy 9 (10.8) 125 (11.5) 0.85
Direct stenting 42 (50.6) 584 (53.8) 0.57
Post-dilation 71 (85.5) 888 (81.8) 0.40
Stent diameter, mm 2.85 0.32 2.98 0.36 0.01
Stent length, mm 22.7 6.8 23.0 6.8 0.66
Maximum balloon diameter,
mm
2.97 0.42 3.09 0.42 0.01
Maximum balloon inﬂation, atm 18.1 3.6 17. 7 4.0 0.50
Pre-intervention
Reference, mm 2.49 0.44 2.68 0.59 0.01
Minimum lumen diameter,
mm
0.60 0.46 0.68 0.49 0.15
% stenosis 75.7 18.2 74.3 17.4 0.48
Lesion length, mm 19.9 7.9 19.6 7.0 0.71
Post stenting
Reference, mm 2.73 0.47 2.84 0.50 0.06
Minimum lumen diameter,
mm
2.63 0.47 2.74 0.51 0.06
% stenosis 2.0 9.4 2.9 9.4 0.41
Values are n (%) or mean SD.
AHA/ACC American Heart Association/American College of Cardiology.ollow-up angiography (8.3  2.2 months). Quantitative
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126oronary angiography results are presented in Table 3.
estenosis was observed in 122 lesions (7.4%). Coronary
ngiography 2-years (1.9 0.4 years) after SES deployment
as performed in 1,168 lesions (74% of lesions without
estenosis at 8-month follow-up). Late restenosis was ob-
erved in 83 lesions (7.1%). Of these, 27 (2.3%) were
ssociated with symptoms. There was significant decrease in
LD between post-procedure and 8-month follow-up
2.71  0.51 mm vs. 2.43  0.74 mm, p  0.001) and
etween 8-month and 2-year follow-up (2.56  0.56 mm
s. 2.35  0.71 mm, p  0.001). Late luminal loss
easured 0.17 0.51 mm and delayed late luminal loss was
Table 3. Quantitative Angiographic Results
Before
Post-
Stenting 8 Months 2 Years
Lesions studied at 8 months
(n  1,659)
Reference (mm) 2.67 0.58 2.82 0.50 2.82 0.49 NA
MLD (mm) 0.66 0.48 2.71 0.51 2.43 0.74 NA
% stenosis 74.8 17.3 3.1 9.4 14.5 21.8 NA
Lesions studied at 2 yrs
(n  1,168)
Reference (mm) 2.66 0.58 2.84 0.50 2.82 0.49 2.79 0.47
MLD (mm) 0.68 0.49 2.73 0.51 2.56 0.56 2.35 0.71
% stenosis 74.4 17.4 2.9 9.4 9.9 13.6 17.5 21.1
Values are mean SD.
MLDminimum lumen diameter; NA not applicable.
Table 4. Baseline Characteristics
Overall
2-Year Follow-Up
p ValueYes No
Age, yrs 68.4 10.3 66.1 8.9 71.2 11.7 0.01
Male 974 (69.9) 572 (74.0) 180 (67.9) 0.06
Hypertension 1,126 (80.8) 614 (79.4) 217 (81.9) 0.39
Hypercholesterolemia 662 (47.5) 394 (51.0) 125 (47.2) 0.29
Diabetes mellitus 526 (37.8) 275 (35.6) 94 (35.5) 0.98
Oral hypoglycemic 450 (32.3) 241 (31.2) 79 (29.8) 0.68
Insulin treatment 76 (5.5) 34 (4.4) 15 (5.7) 0.40
Current smokers 355 (25.5) 216 (27.9) 62 (23.4) 0.15
Chronic renal failure* 67 (4.8) 20 (2.6) 12 (4.5) 0.11
Dialysis dependent 15 (1.1) 8 (1.0) 0 (0) 0.21
Prior myocardial infarction 464 (33.3) 267 (34.5) 74 (27.9) 0.05
Prior PCI 809 (58.1) 482 (62.4) 153 (57.7) 0.18
Prior bypass surgery 88 (6.3) 47 (6.1) 16 (6.0) 0.98
Multivessel disease 685 (49.2) 354 (45.8) 131 (49.4) 0.31
Clinical presentation at initial
procedure
0.58
Acute myocardial infarction 225 (16.2) 121 (15.7) 45 (17.0)
Unstable angina 153 (11.0) 71 (9.2) 29 (10.9)
Stable angina 1,015 (72.9) 581 (75.2) 191 (72.1)
Values are mean SD or n (%). *Creatinine1.5 mg/l.wAbbreviations as in Table 1..20  0.63 mm. Figure 1 demonstrates changes in MLD
etween lesions with and without late restenosis. There was
o significant difference in MLD after the procedure
etween the 2 groups. However, MLD at 8-month
ollow-up was significantly smaller in lesions with late
estenosis. Multivariate analysis showed in-stent restenosis
efore SES implantation and MLD at 8-month follow-up
s independent predictors of late restenosis (Table 6).
iscussion
he present study demonstrated decrease in MLD between
-month and 2-year follow-up in lesions undergoing SES
mplantation, which resulted in late restenosis in some
esions. Minimum lumen diameter at 8-month follow-up
as smaller in lesions with late restenosis than in those
Table 5. Angiographic and Procedural Characteristics
Overall
2-Year Follow-Up
p ValueYes No
Vessels treated 0.08
Left anterior descending 940 (46.8) 553 (47.3) 190 (51.5)
Left circumﬂex 433 (21.6) 244 (20.9) 87 (23.6)
Right coronary artery 588 (29.3) 349 (29.9) 83 (22.5)
Left main artery 43 (2.1) 21 (1.8) 8 (2.2)
Saphenous vein graft 4 (0.2) 1 (0.09) 1 (0.3)
Ostial location 211 (10.5) 117 (10.0) 47 (12.7) 0.14
Bifurcation 461 (23.0) 265 (22.7) 101 (27.4) 0.07
Thrombotic lesion 161 (8.0) 90 (7.7) 28 (7.6) 0.94
Moderate or severe calciﬁcation 391 (19.5) 191 (16.4) 78 (21.1) 0.04
Chronic total occlusion 52 (2.6) 27 (2.3) 8 (2.2) 0.87
In-stent restenosis 154 (7.7) 103 (8.8) 18 (4.9) 0.01
AHA/ACC type B2 or C 1,714 (85.4) 981 (84.0) 312 (84.6) 0.80
Intravascular ultrasound 1,614 (80.4) 968 (82.9) 297 (80.5) 0.29
Rotational atherectomy 258 (12.8) 134 (11.5) 43 (11.7) 0.92
Direct stenting 991 (49.4) 626 (53.6) 175 (47.4) 0.04
Post-dilation 1,573 (78.3) 959 (82.1) 279 (75.6) 0.01
Stent diameter, mm 2.95 0.36 2.97 0.36 2.97 0.37 0.96
Stent length, mm 23.1 7.0 23.0 6.8 23.2 6.8 0.68
Maximum balloon diameter, mm 3.06 0.43 3.08 0.43 3.07 0.44 0.62
Maximum balloon inﬂation, atm 17. 6 4.0 17.8 4.0 17. 8 3.9 0.88
Pre-intervention
Reference, mm 2.65 0.56 2.67 0.58 2.73 0.56 0.06
Minimum lumen diameter, mm 0.63 0.47 0.68 0.49 0.65 0.49 0.46
% stenosis 75.7 17.2 74.4 17.4 75.7 17.1 0.20
Lesion length, mm 19.6 7.2 19.6 7.1 19.8 7.4 0.66
Post stenting
Reference, mm 2.81 0.50 2.83 0.50 2.85 0.49 0.60
Minimum lumen diameter, mm 2.70 0.50 2.73 0.51 2.74 0.51 0.77
% stenosis 3.1 9.4 2.9 9.4 3.6 8.9 0.17
Values are n (%) or mean SD.
Abbreviations as in Table 2.ithout late restenosis. In-stent restenosis before SES
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127mplantation and MLD at 8-month follow-up were inde-
endent predictors of late restenosis.
ate restenosis. Several randomized clinical trials have
emonstrated dramatic decrease in angiographic and clinical
estenosis 6 to 12 months after drug-eluting stent implan-
ation compared with bare-metal stents (1–3). The 2-year
ooled analysis of the sirolimus-eluting balloon-expandable
tent in the treatment of patients with de novo native
oronary artery lesion studies—SIRIUS (Sirolimus-Eluting
tent in Coronary Lesions), E-SIRIUS (European
IRIUS), and C–SIRIUS (Canadian SIRIUS)—reported
he sustained efficacy and safety of SES compared with
are-metal stents (14). In 758 patients, 12 lesions (1.6%)
nderwent TLR at 271 to 720 days after SES implantation.
owever, none of them underwent late TLR for in-stent
estenosis; 1 SES was required for significant residual target
essel disease that was not addressed during the index
rocedure, 2 were required for late SES thrombosis, and the
emaining 9 TLR were performed for peristent restenosis
nd/or progression of disease. By contrast, in a porcine
oronary model, delayed neointimal hyperplasia after SES
mplantation was demonstrated (7). After 30 days, the mean
eointimal area was significantly less for SES compared
ith the control stents (1.40  0.35 mm2 vs. 2.94  1.28
m2, p 0.001). However, it was not significantly different
t 90 (3.03 0.92 mm2 vs. 3.45 1.09 mm2, p NS) and
80 days (3.34 0.99 mm2 vs. 3.65 1.23 mm2, p NS).
ecently, Byrne et al. (8) showed 6- to 8-month and 2-year
ollow-up angiography results in patients who underwent
ES, polymer-free SES, or paclitaxel-eluting stent implan-
ation. At 6- to 8-month follow-up, in-segment restenosis
ates were 12.1% for SES, 17.2% for polymer-free SES, and
7.2% for paclitaxel-eluting stents. At 2-year follow-up, late
n-segment restenosis was observed in 92 (13.1%) of 704
Figure 1. Serial Changes in MLD
Note that only lesions undergoing 8-month and 2-year follow-up angiogra-
phy were included. Statistical analysis was not applied because of the
deﬁnition of the groups. MLD  minimum lumen diameter; NS  not
signiﬁcant.esions with SES, 27 (7.2%) of 375 lesions with polymer-ree SES, and 75 (15.0%) of 501 lesions with paclitaxel-
luting stents. The ISAR-TEST-2 (Intracoronary Stenting
nd Angiographic Results: Test Efficacy of Three Limus-
luting Stents) study (9) compared safety and efficacy
mong SES, a polymer-free sirolimus- and probucol-eluting
tent, and zotarolimus-eluting stent. It has shown that
dditional restenosis between 1 and 2 years was significantly
ower in the dual–drug-eluting stent group (2.9%) than in
he SES group (6.6%) (p  0.023) but comparable to that
bserved with zotarolimus-eluting stent (1.6%) (p  0.28).
osgrave et al. (6) demonstrated a late restenosis rate of
.6% when angiography 1 year after SES implantation
as performed only in symptomatic patients. In the present
tudy, late restenosis was observed in 83 lesions (7.1%). Of
hese, 27 (2.3%) were associated with symptoms. Thus, the
ifference may be explained by mandatory late angiographic
ollow-up.
Serial angiographic studies demonstrated an increase in
LD between 6- and 12-month follow-up after bare-
etal stent implantation (15,16). In the TAXUS II trial
17), there was significant increase in MLD between
-month and 2-year follow-up after bare-metal stent im-
lantation. By contrast, quantitative coronary angiography
id not show significant difference in MLD after paclitaxel-
luting stent implantation (17). The present study showed
ecrease in MLD beyond 8 months after SES implantation.
t 8-month follow-up, MLD was significantly smaller in
esions with late restenosis than in those without late
estenosis (Fig. 1). Furthermore, MLD at 8-month
ollow-up was an independent predictor of late restenosis. A
umber of lesion- and procedure-related factors are associ-
ted with progression of intimal hyperplasia (18). Because of
eterogeneity in lesions undergoing SES implantation,
irolimus from SES may not be sufficient in all lesions to
nhibit progression of intimal hyperplasia (19). Insufficient
irolimus may make neointima formation slow in some
esions, where smaller MLD at 8-month follow-up and late
estenosis at longer follow-up might be observed (7). De-
loyment of SES for in-stent restenosis was another inde-
endent predictor of late restenosis. The SISR (Sirolimus-
Table 6. Multivariate Predictors of Late Restenosis
Variables OR 95% CI p Value
Prior myocardial infarction 0.56 0.31–1.00 0.051
Prior bypass surgery 0.18 0.02–1.33 0.09
In-stent restenosis 2.27 1.05–4.92 0.04
Stent diameters 0.36 0.09–1.43 0.15
Maximum balloon diameter 2.20 0.64–7.54 0.21
Reference before procedure 0.63 0.33–1.22 0.17
MLD after stenting 1.95 0.71–5.34 0.20
MLD at 8-month follow-up 0.32 0.13–0.82 0.02
% stenosis at 8-month follow-up 1.01 0.98–1.04 0.50CI confidence interval; OR odds ratio; other abbreviations as in Table 3.
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128luting Stents Versus Vascular Brachytherapy for In-Stent
estenosis) trial evaluated efficacy of SES for in-stent
estenosis after bare-metal stent implantation (20). It
howed 9-month and 3-year TLR rates of 8.5% and 17.8%,
espectively, that were higher compared with those in de
ovo lesions in other clinical trials (1–3). Lesions with
n-stent restenosis may be prone to have more enhanced
ntimal hyperplasia (21,22).
tudy limitations. In the present study, there was no bare-
etal stent control group. However, previous studies
howed increase in MLD beyond 6 months after bare-metal
tent implantation (15,16). By contrast, the present study
emonstrated decrease in MLD between 8-month and
-year follow-up in lesions undergoing SES implantation.
ollow-up coronary angiography was not performed in all
atients. Incomplete follow-up angiography might result in
lower late restenosis rate. Of 2,008 lesions, 83% under-
ent 8-month follow-up angiography. Coronary angiogra-
hy 2 years after SES deployment was performed in 74% of
esions without restenosis at 8-month follow-up angiogra-
hy. These are similar to other serial angiographic studies
5,8,9).
onclusions
inimum lumen diameter decreases between 8-month and
-year follow-up after SES implantation, which results in
ate restenosis in some lesions. In-stent restenosis before
ES implantation and MLD at 8-month follow-up are
ndependent predictors of late restenosis.
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